Loading…
Fierce Drug Dev Forum 2019 has ended
avatar for Rahul Dhanda

Rahul Dhanda

SHERLOCK BIOSCIENCES
CEO and President
Rahul K Dhanda is a founder and is the president and chief executive officer of Sherlock Biosciences. He also serves on the company’s Board of Directors. Most recently, Mr. Dhanda spent 10 years at T2 Biosystems where he helped grow the company from an early-staged, venture-backed startup to a commercial, publicly-traded leader in infectious disease diagnostics where he held the role of senior vice president of corporate development and marketing. At T2 Biosystems, he had an expansive role where he led the company’s strategy, marketing, product management and all corporate deal activity, the latter of which brought over $40 million in funding to the company.

Prior to joining T2 Biosystems, Mr. Dhanda worked in Boston Scientific’s urology division, where he led a team responsible for over $100 million in annual revenue. Prior to Boston Scientific, Mr. Dhanda held a business development role at Interleukin Genetics, where he helped lead the negotiation of the firm’s acquisition by Alticor, Inc. as well as multiple other corporate value-creating deals.

Mr. Dhanda earned his MBA. from MIT’s Sloan School of Management and his B.A. from Wesleyan University. He is a former committee member of the AAAS Committee on Scientific Freedom and Responsibility. Mr. Dhanda is the author of several publications, an inventor on numerous patents, and has authored the first book to address the crossroads between industry and bioethics/public policy, entitled Guiding Icarus: Merging Bioethics with Corporate Interests.